×
About 9,303 results

ALLMedicine™ Bone Metastases Center

Research & Reviews  2,837 results

Development and validation of MRI-based radiomics signatures as new markers for preoper...
https://doi.org/10.1186/s12885-022-09985-4
BMC Cancer; Fan Y, Dong Y et. al.

Aug 14th, 2022 - This study aimed to develop and externally validate contrast-enhanced (CE) T1-weighted MRI-based radiomics for the identification of epidermal growth factor receptor (EGFR) mutation, exon-19 deletion and exon-21 L858R mutation from MR imaging of s...

Parathyroid hormone-related protein (PTHrP) and malignancy.
https://doi.org/10.1016/bs.vh.2022.03.002
Vitamins and Hormones; Grunbaum A, Kremer R

Aug 12th, 2022 - PTHrP (parathyroid hormone related protein) is an important mediator of malignancy-related tumor progression and hypercalcemia that shares considerable homology and functionality with parathyroid hormone. In this chapter, we review what has been e...

Parathyroid hormone-related protein in breast cancer bone metastasis.
https://doi.org/10.1016/bs.vh.2022.04.006
Vitamins and Hormones; Johnson RW, Rhoades J et. al.

Aug 12th, 2022 - Parathyroid hormone-related protein (PTHrP) was discovered as the tumor product causing the humoral hypercalcemia of malignancy. Its structural similarity to the hormone, PTH, with 8 of the first 13 amino acids identical, was sufficient to explain...

Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases
https://clinicaltrials.gov/ct2/show/NCT02803437

Aug 10th, 2022 - This is a local, non-interventional, multi-center, single-cohort study using primary data of patients treated with Xofigo for the indication of castration resistant prostate cancer (CRPC) with bone metastases. A total of 300 patients (valid for sa...

Validating the screening criteria for bone metastases in treatment-naïve unfavorable in...
https://doi.org/10.1007/s00330-022-08945-7
European Radiology; Rud E, Noor D et. al.

Aug 9th, 2022 - The European Association of Urology (EAU) recommends a bone scan for newly diagnosed unfavorable intermediate- and high-risk prostate cancer. We aimed to validate the screening criteria for bone metastases in patients with treatment-naïve prostate...

see more →

Guidelines  6 results

SEOM Clinical Guideline for bone metastases from solid tumours (2016).
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5138247
Clinical & Translational Oncology : Official Publication ... Grávalos C, Rodríguez C et. al.

Nov 30th, 2016 - Bone metastases are common in many advanced solid tumours, being breast, prostate, thyroid, lung, and renal cancer the most prevalent. Bone metastases can produce skeletal-related events (SREs), defined as pathological fracture, spinal cord compre...

Bone health in cancer patients: ESMO Clinical Practice Guidelines.
https://doi.org/10.1093/annonc/mdu103
Annals of Oncology : Official Journal of the European Soc... Coleman R, Body JJ et. al.

May 2nd, 2014 - There are three distinct areas of cancer management that make bone health in cancer patients of increasing clinical importance. First, bone metastases are common in many solid tumours, notably those arising from the breast, prostate and lung, as w...

Prostate cancer, version 1.2014.
https://doi.org/10.6004/jnccn.2013.0174
Journal of the National Comprehensive Cancer Network : JN... Mohler JL, Kantoff PW et. al.

Dec 18th, 2013 - The NCCN Guidelines for Prostate Cancer provide multidisciplinary recommendations on the clinical management of patients with prostate cancer. This report highlights notable recent updates. Radium-223 dichloride is a first-in-class radiopharmaceut...

SEOM guidelines for the treatment of bone metastases from solid tumours.
https://doi.org/10.1007/s12094-012-0832-0
Clinical & Translational Oncology : Official Publication ... Cassinello Espinosa J, González Del Alba Baamonde A et. al.

Jun 23rd, 2012 - Bone metastases are a common and distressing effect of cancer, being a major cause of morbidity in many patients with advanced stage cancer, in particular in breast and prostate cancer. Patients with bone metastases can experience complications kn...

Experts' agreement on therapy for bone metastases.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6583368
Orthopaedic Surgery; Du ZY, Zang J et. al.

Oct 20th, 2011 - Experts' agreement on therapy for bone metastases.|2011|Du ZY,Zang J,Tang XD,Guo W, ,|diagnosis,secondary,therapy,pathology,secondary,surgery,pathology,surgery,pathology,surgery,secondary,surgery,

see more →

Drugs  43 results see all →

Clinicaltrials.gov  376 results

Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases
https://clinicaltrials.gov/ct2/show/NCT02803437

Aug 10th, 2022 - This is a local, non-interventional, multi-center, single-cohort study using primary data of patients treated with Xofigo for the indication of castration resistant prostate cancer (CRPC) with bone metastases. A total of 300 patients (valid for sa...

Fluciclovine-PET/CT for Bone Metastases From Prostate Adenocarcinoma
https://clinicaltrials.gov/ct2/show/NCT03496844

Aug 9th, 2022 - Determine diagnostic accuracy of Axumin-PET positive bone lesion by confirmatory bone biopsy.

68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Progression During Androgen Deprivation Therapy
https://clinicaltrials.gov/ct2/show/NCT04928820

Aug 3rd, 2022 - PRIMARY OBJECTIVE: I. To compare the per-patient detection rate of 68Ga-PSMA-11 PET/CT versus bone scan (BS)/CT for M1b in patients treated with androgen deprivation therapy (ADT) who are referred for the imaging evaluation of disease progression....

Effect of Zoledronic Acid Treatment on Bone-related Events in Breast Cancer Patients With Bone Metastases: a Prospective, Multicenter, Real-world Study
https://clinicaltrials.gov/ct2/show/NCT05480189

Jul 29th, 2022 - (1) Main Purpose: To observe the clinical efficacy of zoledronic acid regularly in the prevention of SREs in breast cancer patients with bone metastasis (2) Secondary Objectives: To observe whether zoledronic acid prolonged the time of first SREs ...

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma
https://clinicaltrials.gov/ct2/show/NCT02306161

Jul 28th, 2022 - PRIMARY OBJECTIVES: I. To determine if event-free survival (EFS) in patients with newly diagnosed metastatic Ewing sarcoma treated with multiagent chemotherapy is improved with the addition of ganitumab (AMG 479). SECONDARY OBJECTIVES: I. To descr...

see more →

News  457 results

Overall Survival Gain With Adding Darolutamide to ADT and Docetaxel in Metastatic, Hormone-Sensitive Prostate Cancer
https://www.mdedge.com/jcomjournal/article/255042/oncology/overall-survival-gain-adding-darolutamide-adt-and-docetaxel
Santosh Kagathur, MD, Daniel Isaac, DO, MS

May 27th, 2022 - Study Overview Objective: To evaluate whether the addition of the potent androgen-receptor inhibitor (ARA) darolutamide to the standard doublet androgen-deprivation therapy (ADT) and docetaxel in metastatic, hormone-sensitive prostate cancer (mHSP.

Prognostic factors in male breast cancer with bone metastases
https://www.mdedge.com/hematology-oncology/article/254754/breast-cancer/prognostic-factors-male-breast-cancer-bone

May 18th, 2022 - Key clinical point: Age, tumor subtype, surgery, and brain metastasis are independent risk factors for survival in male patients with breast cancer (BC) and bone metastases and should be considered when devising a treatment strategy. Major finding.

Renal Cell Carcinoma: Future Directions in Care
https://www.onclive.com/view/renal-cell-carcinoma-future-directions-in-care

May 2nd, 2022 - Transcript: Robert J. Motzer, MD: Two last quick points for you. Cabozantinib is 1 of our main go-to drugs for RCC [renal cell carcinoma]. It’s been proposed to be particularly effective for bone metastases, right? There were recent data for cabo...

Patient Profile 2: 3L Therapy for Triple-Positive mBC
https://www.onclive.com/view/patient-profile-2-3l-therapy-for-triple-positive-mbc

May 2nd, 2022 - Transcript: Neil Iyengar, MD: [This patient] sustained her response. It was a durable response, for about a year. In early 2022, unfortunately, we found progression with new bone metastases and a new liver lesion. She has viscerally driven diseas...

Selecting Optimal Therapy for mHSPC: Design of the ARASENS Trial
https://www.onclive.com/view/selecting-optimal-therapy-for-mhspc-design-of-the-arasens-trial

May 2nd, 2022 - Transcript: Alicia Morgans, MD, MPH: From your perspective, Evan, as you’re thinking about putting patients on trial or treating them in clinic, what are some clinical factors or disease-related factors you think about as you’re thinking about tr...

see more →

Patient Education  2 results see all →